Oncology Meeting Digest

Prostate

1 study across 1 date

2026-05-17

PRIME trial — pelvic-nodal SBRT vs moderate hypofractionation in high-risk prostate cancer

PRIME compares SBRT (36.25 Gy/5#) vs moderate hypofractionation (~68 Gy/25#), both with pelvic nodal RT and ADT, in aggressive prostate cancer.

  • Moderate hypofractionation: ~68 Gy/25#/5 weeks; SBRT: 36.25 Gy/5#/1-2 weeks; both arms include pelvic nodal coverage.
  • No primary endpoint result or toxicity data in source tweet; images (tweet 4, images 13-14) not accessible.
  • HYPO RT-PC established extreme hypofractionation non-inferiority for prostate-only RT — PRIME extends this to simultaneous pelvic nodal SBRT, a meaningfully higher bowel-toxicity scenario.
  • PEACE II (tweet 1 context): established WPRT + 3y ADT benefit over prostate-only RT in high-risk disease — PRIME tests whether that nodal benefit is deliverable in 5 fractions.
  • POP RT (tweet 1): 2y ADT + WPRT comparator — ADT duration and field size interact; PRIME results require ADT duration context for valid benchmarking.
  • Principal safety concern: rectal and bowel dose constraints for large-field pelvic SBRT at 36.25 Gy equivalent are not established in phase III data — this is the main gap PRIME addresses.
📚 Sources (2)